Good post Stockrock. My view is that if Mesoblast discover a therapy that reduces deaths from heart failure by 60 percent and the stock tanks then management will have great difficulty staying in charge of the company. This issue adds to the FDA rejection of another effective therapy just a few months ago.
9 hours ago
well thought out and written. Thankyou
22 hours ago
3 or 4 IMHO thanks for intelligent thoughts- couldn’t agree more-- thought trial results epic funny how mrkt misread—60% reduction mortality and MACE—epic and unparalleled
MSB Price at posting:
$3.77 Sentiment: Buy Disclosure: Held
(20min delay)